Seneszenz-induzierte Modulation des Tumormikromilieus im Pankreaskarzinom verbessert das Therapieansprechen

Sebastian Krug; Patrick Michl

doi:10.1055/a-1238-9909

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2020; 58(12): 1267-1268
DOI: 10.1055/a-1238-9909

Kommentiertes Referat

Seneszenz-induzierte Modulation des Tumormikromilieus im Pankreaskarzinom verbessert das Therapieansprechen

Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer Cell 2020; 181: 424–441

Authors

Sebastian Krug

Martin-Luther-Universität Halle/Wittenberg, Klinik und Poliklinik für Innere Medizin I, Halle/Saale
Patrick Michl

Martin-Luther-Universität Halle/Wittenberg, Klinik und Poliklinik für Innere Medizin I, Halle/Saale

Abstract

Full Text

References

Literatur
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34
2 Golan T, Hammel P, Reni M. et al. Maintenance Olaparib for Germline. N Engl J Med 2019; 381: 317-327
3 Golan T, Kindler HL, Park JO. et al. Geographic and Ethnic Heterogeneity of Germline. J Clin Oncol 2020; 38: 1442-1454
4 Hessmann E, Buchholz SM, Demir IE. et al. Microenvironmental Determinants of Pancreatic Cancer. Physiol Rev 2020; 100: 1707-1751
5 Caldwell ME, DeNicola GM, Martins CP. et al. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2012; 31: 1599-1608
6 Tao Z, Le Blanc JM, Wang C. et al. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Clin Cancer Res 2016; 22: 122-133
7 Ziemke EK, Dosch JS, Maust JD. et al. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. Clin Cancer Res 2016; 22: 405-414
8 Ruscetti M, Leibold J, Bott MJ. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 2018; 362: 1416-1422
9 Provenzano PP, Cuevas C, Chang AE. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429
10 Ramanathan RK, McDonough SL, Philip PA. et al. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol 2019; 37: 1062-1069
11 Van Cutsem E, Tempero MA, Sigal D. et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020;